TDM1 Study: Breast Cancer

A Prospective, Randomized, Open-label, Parallel Group, Active-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Proposed Trastuzumab Emtansine Biosimilar Compared with Kadcyla® in HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Treatment with Trastuzumab and a Taxane